Open in interactive viewer → charts, metric popovers & call review

Bavarian Nordic's Rabies Rocket Has a Wholesaler Stowaway

A new CEO inherits a 34% EBITDA margin, a US rabies market growing ~50% monthly, and two questions management has now answered the same non-answer way for a second straight quarter
BAVA.CO · Earnings Call · 2026-11-13

The number that isn't the story

On the surface, Bavarian Nordic's Q3 2026 print is a rounding error: revenue growth of 0.6% in the quarter, 2% for the nine months. That is the arithmetic of a company that amputated two partner relationships. Strip out the discontinued partnerships with Valneva and Dynavax and the organic picture is over 9% growth for the nine months, with EBITDA margin of near 35% — a figure management itself calls "extraordinary" against a previously stated 25%–30% ambition. The distortion runs the other way too. Last year's Q3 contained an DKK 810 million priority review voucher sale; back that out and the 34.4% margin this quarter is a roughly six-point improvement, not a collapse. “If you deduct that from the EBITDA, then you're actually comparing to a 28% EBITDA last year. So we are up 6 percentage points in terms of profitability as well.” — Henrik Juuel, Chief Financial Officer (CFO) · 2026-11-13 So the headline is noise. The signal is underneath it, and there are three of them.

One: rabies is a company-unique engine, and nobody can tell you how big the fuel tank is

The Rabies business is the entire story of 2026. It grew 38%–39% over nine months, driven by a US market that has grown 36% year-to-date and, on a monthly basis, has accelerated to roughly 50%. Henrik Juuel's explanation is epidemiological rather than commercial: rabies is endemic, hotspots are spreading across states, the disease is jumping species beyond bats, and media coverage of human-to-animal encounters is pulling forward pre-exposure demand. “As this is a deadly disease, there's a lot of media attention around these statistics. And that, again, that media attention creates a demand for vaccinations ahead of any risks.” — Henrik Juuel, Chief Financial Officer (CFO) · 2026-11-13 It is a genuinely company-unique theme. Across twelve quarters of the market's own top-75 keyword lists — tariffs, AI data centers, Fed hikes, hurricanes — rabies, chikungunya, travel vaccines do not appear once. Bavarian Nordic is not riding a wave here; it is the wave. That cuts both ways: no sector beta to lean on, and no sector beta to hide behind. Which brings us to the recurring irritation. Analyst Hakon Hemme asked directly whether Q3 was pure underlying demand or whether wholesaler inventory movements also contributed — because at the Q2 call, the same management had conceded the buildup amplified growth. The answer was honest and unsatisfying: “That happened during Q2. It probably also happened here during Q3. That is simply just an effect of such a rapid increase. And it's difficult for us to separate the effects really.” — Henrik Juuel, Chief Financial Officer (CFO) · 2026-11-13 The wholesaler level ambiguity has now run for at least three quarters — it was flagged in Q1, conceded in Q2, and re-conceded in Q3. It is not a red flag so much as an unpriced option: if the US curve is real demand, the number is far too low; if it is safety stock, some of it unwinds. Management's own summary is that they “see no signs that the market should decline again” — Operator, Operator · 2026-11-13 — but also that it is "a difficult market to forecast."

Two: Vimkunya's US excuse is ageing, and Europe is doing the work

The chikungunya vaccine delivered DKK 151 million over nine months against a DKK 200 million full-year target. Germany has exceeded expectations; the US has not. The stated cause is the same one offered in May and August: the ACIP recommendation has not been published in the MMWR publication, and the CDC's definition of a current outbreak is unusually restrictive — only three countries listed versus more than fifteen on the European side. It is a real bottleneck, and distributors really do stall without the publication. But the clock matters: the prior CEO said in May that publication "can take anywhere from 12 to 18 months." That was six months ago, and the company is still guiding to a target that assumes it happens in 2026. Hakon's question — what does the 2027 ramp look like if it doesn't — went largely unanswered, which is itself the answer. The Vimkunya launch also carries a modelling trap Juuel was upfront about: “don't expect sort of a smooth curve because we are launching into many countries... it will not -- probably not be a smooth curve.” — Henrik Juuel, Chief Financial Officer (CFO) · 2026-11-13 A DKK 200 million target on a lumpy launch into dozens of health systems is not a forecast; it's a direction of travel.

Three: the quiet walk-back, and a CEO who says "semantics"

This is the most interesting thing on the call, and it was buried in the Q&A. In August, Paul Chaplin said of Public preparedness: “we've been saying DKK 1.5 billion, DKK 2 billion base business, I think we're becoming more and more comfortable that we're going to be in the region at the upper end of that, around the DKK 2 billion mark.” — Paul Chaplin, Interim CEO · 2026-08-21 On this call, that comfort was formally retracted — not contradicted, retracted into procedure: “we have not officially changed our guidance on that one. So our medium-term guidance. It remains DKK 1.5 billion to DKK 2 billion.” — Henrik Juuel, Chief Financial Officer (CFO) · 2026-11-13 Meanwhile the business is delivering DKK 2.5 billion this year, against a DKK 2.4 billion contracted for 2026 and around DKK 900 million secured for 2027. The base business level is being deliberately un-raised until the mid-term targets expire at the end of next year — at which point a new number will be minted alongside a new strategy. Until then, the company keeps a sandbag it has already publicly outgrown. That is consistent with the arrival of Tarja Stenvall, one month into the job, who spent her opening remarks sketching a strategic review — travel health growth, deeper government partnerships, manufacturing footprint, M&A — with priorities and an approach to capital allocation to be shared in H1 2027. Analyst Peter Hugreffe pushed: is this a review or just execution? “Yes, maybe this is semantics.” — Tarja Stenvall, Chief Executive Officer (CEO) · 2026-11-13 It is a fair deflection and a telling one — the strategy has not changed yet, the framing has.

I've now been with the Bavarian Nordic for about a month, and naturally, I am still in the listening and learning phase... The objective is simple, to make clear choices about where we focus our efforts and investments to create long-term value.

Tarja Stenvall, Chief Executive Officer (CEO) · 2026-11-13
Capital return is already speaking louder than the review. The first DKK 750 million tranche of the buyback completed in October; a second tranche of up to DKK 150 million started the morning of the call, with nearly DKK 3 billion of cash still on the balance sheet and no debt. M&A stays in the strategy, with an unusually explicit filter: revenue-generating from day one, not dilutive to profitability, and fitting the existing commercial organization.

The tension worth watching

Add it up. A new CEO still listening. A CFO exiting next spring, insisting there's "absolutely no drama." A guidance framework that bends the margin toward Q4 conservatism — “we are probably on the conservative side” — Henrik Juuel, Chief Financial Officer (CFO) · 2026-11-13 — while the underlying rabies franchise compounds at a rate no one will underwrite. An FDA-adjacent bottleneck in the US that has now been "short-term" for two quarters. And a Public Preparedness base that has quietly been pushed back into its old range just as it prints its best year in memory. The stock question is not whether Q3 was good. It was. It's whether a business whose growth is concentrated in one life-saving vaccine, amplified by an unmeasurable wholesaler effect, and whose second growth driver is waiting on a government publication, deserves to be valued on the momentum or on the base. Management has bought itself until H1 2027 to answer. The wholesalers may answer first.